Heart Failure 2019 - 6th World Congress on Acute Heart Failure

25 - 28 May 2019, Athens - Greece

Session Details

Poster Session 3: Chronic Heart Failure – Treatment
Mon 27 May 08:30 - 18:00 Other Poster Session Poster Area - Poster Area

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
08:30P1649Effects of mineralocorticoid ceceptor antagonists (MRA) in heart failure patients after up to 12 months of follow-up.Lisa Lauren BUTTIGIEG (Attard, Malta)
08:30P1650Sacubitril valsartan, a multicentric experienceFrancisco Javier CORTES (Sevilla, Spain)
08:30P1651Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapyBranimir KANAZIREV (Varna, Bulgaria)
08:30P1652Effects of sacubitril/valsartan on real-world patients with heart failure due to non-ischemic cardiomyopathyChien-Yi HSU (Taipei City, Taiwan, Province of China)
08:30P1653Effects of ivabradine on patients with depressed left ventricular ejection fraction after cardiac resynchronization therapyChao-Wen HSIEH (Taipei, Taiwan, Province of China)
08:30P1654Benefits of early administration of ivabradine in stabilized patients hospitalized due to worsening heart failure: insights from the Optimize Heart Failure Care ProgramLilyana MIRCHEVA (Varna, Bulgaria)
08:30P1655Series of patients treated with sacubitril-valsartan in a cardiology day clinic: efficacy and safety after 6 months of follow-up Cristina BELTRAN HERRERA (Madrid, Spain)
08:30P1656Effects of empagliflozin on exercise capacity and LV diastolic function in HFpEF and type-2 diabetes mellitus: rationale and design of prospective intervention studyAnton BORISOV (Lytkarino, Russian Federation)
08:30P1658Titration process and predictors of achieving target dose of sacubitril/valsartan in patients with chronic heart failure and reduced ejection fraction attending to an outpatient heart failure clinic.Marcelo RIZZO (Barcelona, Spain)
08:30P1659Nitrates in female patients with diabetes mellitus and without diabetes mellitus in reduced ejection fraction heart failureDilek URAL (Istanbul, Turkey)
08:30P1660Microcirculation changes in combination therapy in patients with heart failure with preserved ejection fraction.Zarina AKHILGOVA (Moscow, Russian Federation)
08:30P1661Effects of perindopril on levels of endothelial dysfunction biomarkers in chronic heart failure patients with mid-range ejection fraction after 12-month therapyIrina ILGISONIS (Moscow, Russian Federation)
08:30P1662Sacubitril/valsartan in chronic symptomatic heart failure: a real world experience of delivery and outcomes.Aileen KEARNEY (Ballymena, United Kingdom of Great Britain & Northern Ireland)
08:30P1663Outpatient inotrope administration in advanced heart failure patients: a single centre experience.James CURTAIN (Dublin, Ireland)
08:30P1664Atrial fibrillation in Dutch chronic heart failure with reduced ejection fraction patients: the CHECK-HF registryJesse Feiko VEENIS (Rotterdam, Netherlands (The))
08:30P1665Reduced diuretic requirements in HFreF patients taking Entresto (ARNI)Laura O'CONNOR (Dublin, Ireland)
08:30P1666Sacubitril/Valsartan in real world heart failure proctice in AsiaPao-Hsien CHU (Taipei, Taiwan, Province of China)
08:30P1667Reduction of loop diuretic requirements in HFrEF patients treated with Sacubitril/ValsartanCristina GOENA VIVES (San Sebastian, Spain)
08:30P1669Recovery of left ventricular dysfunction after Sacubitril/valsartan: predictors and managementsHung-Yu CHANG (Taipei, Taiwan, Province of China)
08:30P1671Safety, tolerability and discontinuation causes of sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction attending to an outpatient heart failure clinic. Marcelo RIZZO (Barcelona, Spain)
08:30P1672Outcomes of adherence to guideline in heart failure management: the role of heart failure specialistHadi SKOURI (Beirut, Lebanon)
08:30P1673Valsartan improves ventriculo-vascular coupling index dose-dependently in heart failure with reduced left ventricular ejection fractionWook-Jin CHUNG (Incheon, Korea (Republic of))
08:30P1674Factors that influence Heart Failure treatment titration in a Heart Failure UnitGonzalo Luis ALONSO SALINAS (Madrid, Spain)
08:30P1676Potentially inappropriate medication use in elderly patients with heart failure: beers criteria-based reviewMariam ZAHWE (Beirut, Lebanon)
08:30P1677Baseline characteristics, treatment dosage, and clinical outcomes of post-acute HFrEF patients initiated with Sacubitril/ValsartanHuai-Wen LIANG (Kaohsiung, Taiwan, Province of China)
08:30P1678Central sleep apnea in patients with chronic heart failure and its treatment with acetazolamideKliya SOROKINA (Moscow, Russian Federation)
08:30P1679The investigation of efficacy and safety about the clinical pathway for congestive heart failure specified immediate use of tolvaptan after admission in super-elderly patients.Yuichi KATO (Kannonji, Japan)
08:30P1680Sacubitril/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension and dose titrationHung-Yu CHANG (Taipei, Taiwan, Province of China)
08:30P1681Sacubitril-valsartan treatment furtherly improves response to intermittent parenteral levosimendan in ambulatory patients with advanced heart failure with reduced ejection fraction Benjamin MUNOZ CALVO (Madrid, Spain)
08:30P1682Significant underutilization of angiotensin receptor neprolysin inhibitor (ARNI) and other evidence-based heart failure (HF) therapies in an outpatient clinic settingNarendra SINGH (Cumming, United States of America)
08:30P1683Effectiveness of early administration of Tolvaptan for cardiac prognosis in acute decompensated heart failureToshio KANEDA (Yokohama, Japan)
08:30P1684Sacubitril/Valsartan: for all patients?Bebiana FARIA (Guimaraes, Portugal)
08:30P1685Effects of statins on major adverse cardiovascular events in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunctionDmytro LASHKUL (Zaporizhzhia, Ukraine)
08:30P1687An evaluation of consultant and registrar prescribing in the outpatient settingClare THOMSON (London, United Kingdom of Great Britain & Northern Ireland)
08:30P1688Frailty quick test, effective for risk stratification of inadequate treatment of heart failureJuan Diego SANCHEZ VEGA (Madrid, Spain)
08:30P1689Effect of sacubitril/valsartan in real-world patients in South LondonNiels HOLM (Zurich, Switzerland)
08:30P1691Impact of beta blockers therapy on right ventricular function in heart failure patients with reduced ejection fraction a prospective evaluationRemi GALVES (Saint Etienne, France)
08:30P1692Clinical experience with ambulatory perfusion of levosimendan in an advanced heart failure unitCarles MOLINER (Barcelona, Spain)
08:30P1693Treatment of patients with chronic heart failure: does management in heart failure clinic improve adherence to guidelines for the treatment of heart failure?Tjasa FURLAN (Ljubljana, Slovenia)
08:30P1694Intermittent infusions of levosimendan in advanced heart failure: last but not least; a single-centre clinical experience on the efficacy of repeated levosimendan infusions.Paola ROMANO (Milan, Italy)
08:30P1695Study of effect of therapy of chronic obstructive pulmonary disease on coexistent chronic heart failure 
08:30P1696Polypharmacy in patients with chronic heart failureMihnea Alexandru GAMAN (Bucharest, Romania)
08:30P1697Changes in hemodynamic profile in patients with severe systolic dysfunction treated with sacubitril-valsartan 
08:30P1698Sacubitril/valsartan inverse remodeling - a prospective echocardiographic study 
08:30P1699Initial clinical experience with the first drug (sacubitril/valsartan) in a new class -arni- in afro-caribbean patients with heart failure and reduced ejection fractionFelix NUNURA (Manchester, Jamaica)
08:30P1700Empagliflozin in heart failure: beyond clinical endpointsSusana DEL PRADO DIAZ (Madrid, Spain)
08:30P1701ARNI use in clinical practice: PARADIGM-HF trial results applied to the real worldJoao AGOSTINHO (Lisboa, Portugal)
08:30P1702MYK-491, a novel cardiac myosin activator, increases cardiac contractility in healthy volunteersJean-Francois TAMBY (San Mateo, United States of America)
08:30P1703Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - A multicenter propensity score matched analysisLutz FRANKENSTEIN (Heidelberg, Germany)
08:30P1704A low dose Pimobendan was observed to prolong the period until re-hospitalization for Japanese patients with advanced heart failure, especially in the vulnerable post-discharge period.Kazuhisa KODAMA (Kumamoto-City, Japan)
08:30P1705microRNA-21 as a prognostic biomarker of sacubitril/valsartan treatment response in heart failure with reduced ejection fraction Maria MARKETOU (Heraklio, Greece)
08:30P1706Metabolism and pharmacokinetic drug interaction profile of vericiguat, a soluble guanylate cyclase stimulatorMaximilian LOBMEYER (Wuppertal, Germany)
08:30P1707Are we optimizing medical therapy during a heart failure hospitalisation ?Kim GIRARD (Sherbrooke, Canada)
08:30P1708Sacubitril/Valsartan in clinical practice, how does it work?Charlotte BACKELIN (Goteborg, Sweden)